Nanjing Leads Biolabs Co., Ltd. (HKG:9887)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
85.85
-8.00 (-8.52%)
Apr 17, 2026, 4:08 PM HKT
Market Cap18.54B
Revenue (ttm)197.25M
Net Income-235.27M
EPS-1.35
Shares Out197.56M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,931,108
Average Volume1,190,370
Open94.10
Previous Close93.85
Day's Range84.85 - 96.55
52-Week Range44.72 - 97.50
Betan/a
RSI75.50
Earnings DateMar 27, 2026

About Nanjing Leads Biolabs

Nanjing Leads Biolabs Co., Ltd., a clinical-stage biotechnology company, engages in the research, development, and commercialisation of novel antibody drugs worldwide. It develops therapies in oncology, autoimmune, and other severe diseases. The company’s lead product LBL-024, a PD-L1/4-1BB bispecific antibody for extra-pulmonary neuroendocrine carcinoma, as well as LBL-034, LBL-033, and LBL-007. In addition, it develops LeadsBody platform, a portfolio of CD3 T-cell engagers that demonstrate anti-tumor efficacy and safety in preclinical/clinica... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Country China
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 9887
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements